Sukanta Chatterjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Sukanta Chatterjee has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Moumita Samanta
Department of Pediatrics, Medical College and Hospital, Kolkata, India
11 shared publicationsMihir Sarkar
Department of Pediatrics and Pediatric Apex HIV clinic, Medical College and Hospital, Kolkata-700073, India
6 shared publications- Mihir Sarkar
Department of Pediatrics, Medical College and Hospital, Kolkata, India
6 shared publications R Chatterjee
6 shared publications- Souvik Mitra
Department of Pediatrics, Medical College and Hospital, Kolkata, India
5 shared publications Kaberi Basu
4 shared publications
Latest Publications
- 19 January 2024
- Published by Springer Nature in Indian Pediatrics
- Vol. 61 (1) , 24-29
Joint Statement on Comprehensive Education for Adolescents and Young People to Support Their Healthy Development and Wellbeing: Adolescent Health Academy, Indian Academy of Pediatrics, Federation of Obstetric and Gynecological Societies of India, Indian Association of Preventive and Social Medicine, and Indian Public Health Association
- 19 January 2024
- Published by Springer Nature in Indian Pediatrics
- Vol. 61 (1) , 24-29
Joint Statement on Comprehensive Education for Adolescents and Young People to Support Their Healthy Development and Wellbeing: Adolescent Health Academy, Indian Academy of Pediatrics, Federation of Obstetric and Gynecological Societies of India, Indian Association of Preventive and Social Medicine, and Indian Public Health Association
- 21 July 2016
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 52 (7) , 704-709
Evaluation of malnutrition as a predictor of adverse outcomes in febrile neutropenia associated with paediatric haematological malignancies
Aim: Malnutrition has been reported in the literature to be adversely associated with outcomes in paediatric malignancies. Our objective in this paper was to evaluate malnutrition as a potential predictor for adverse outcomes in febrile neutropenia associated with haematological malignancies.Methods: A prospective observational study was performed in a tertiary care teaching hospital of Kolkata, India. Forty‐eight participants, suffering from haematological malignancy, were included. Participants were included if they experienced at least one episode of febrile neutropenia. For children aged P = 0.044), and life‐threatening complications show a moderate trend towards significance (OR 3.333, 95% CI 0.791–14.052, one‐tailed P = 0.084). Survival functions were significantly different between malnourished and non‐malnourished children (log rank test χ2 = 4.609, degree of freedom = 1, P = 0.032). Wasting was associated with life‐threatening complications in children aged P = 0.036). Logistic regression analyses at episode level revealed that phase of treatment and respiratory system involvement were significant predictors of death, while malnutrition was not.Conclusion: Malnutrition may be a potential predictor of mortality in febrile neutropenia.
- 21 July 2016
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 52 (7) , 704-709
Evaluation of malnutrition as a predictor of adverse outcomes in febrile neutropenia associated with paediatric haematological malignancies
Aim: Malnutrition has been reported in the literature to be adversely associated with outcomes in paediatric malignancies. Our objective in this paper was to evaluate malnutrition as a potential predictor for adverse outcomes in febrile neutropenia associated with haematological malignancies.Methods: A prospective observational study was performed in a tertiary care teaching hospital of Kolkata, India. Forty‐eight participants, suffering from haematological malignancy, were included. Participants were included if they experienced at least one episode of febrile neutropenia. For children aged P = 0.044), and life‐threatening complications show a moderate trend towards significance (OR 3.333, 95% CI 0.791–14.052, one‐tailed P = 0.084). Survival functions were significantly different between malnourished and non‐malnourished children (log rank test χ2 = 4.609, degree of freedom = 1, P = 0.032). Wasting was associated with life‐threatening complications in children aged P = 0.036). Logistic regression analyses at episode level revealed that phase of treatment and respiratory system involvement were significant predictors of death, while malnutrition was not.Conclusion: Malnutrition may be a potential predictor of mortality in febrile neutropenia.
- Open Access
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial
Objective This study (NCT00969436) compared the immunogenicity and safety of measles-mumps-rubella (MMR) followed by MMR+varicella (V) vaccines to (1) 2 doses of combined MMRV and (2) MMR followed by MMRV, in Indian children. Design Phase III, open, randomised, non-inferiority study. Setting 6 tertiary care hospitals located in India. Participants Healthy participants aged 9–10 months not previously vaccinated against/exposed to measles, mumps, rubella and varicella or without a history of these diseases. Interventions Participants were randomised (2:2:1) to receive 2 doses of either MMRV (MMRV/MMRV group) or MMR followed by MMRV (MMR/MMRV group) or MMR followed by MMR+V (MMR/MMR+V, control group) at 9 and 15 months of age. Antibody titres against measles, mumps and rubella were measured using ELISA and against varicella using an immunofluorescence assay. Main outcome measures To demonstrate non-inferiority of the 2 vaccination regimens versus the control in terms of seroconversion rates, defined as a group difference with a lower bound of the 95% CI >−10% for each antigen, 43 days postdose 2. Parents/guardians recorded solicited local and general symptoms for a 4-day and 43-day period after each vaccine dose, respectively. Results Seroconversion rates postdose 1 ranged from 87.5% to 93.2% for measles, 83.3% to 86.1% for mumps and 98.7% to 100% for rubella across the 3 vaccine groups. The seroconversion rates postdose 2 were 100% for measles, mumps and rubella and at least 95.8% for varicella across the 3 vaccine groups. Non-inferiority of MMRV/MMRV and MMR/MMRV to MMR/MMR+V was achieved for all antigens, 43 days postdose 2. The 3 vaccination regimens were generally well tolerated in terms of solicited local and general symptoms. Conclusions The immune responses elicited by the MMRV/MMRV and MMR/MMRV vaccination regimens were non-inferior to those elicited by the MMR/MMR+V regimen for all antigens. The 3 vaccination schedules also exhibited an acceptable safety profile in Indian children. Trial registration number NCT00969436.
Open AccessImmunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial
Objective This study (NCT00969436) compared the immunogenicity and safety of measles-mumps-rubella (MMR) followed by MMR+varicella (V) vaccines to (1) 2 doses of combined MMRV and (2) MMR followed by MMRV, in Indian children. Design Phase III, open, randomised, non-inferiority study. Setting 6 tertiary care hospitals located in India. Participants Healthy participants aged 9–10 months not previously vaccinated against/exposed to measles, mumps, rubella and varicella or without a history of these diseases. Interventions Participants were randomised (2:2:1) to receive 2 doses of either MMRV (MMRV/MMRV group) or MMR followed by MMRV (MMR/MMRV group) or MMR followed by MMR+V (MMR/MMR+V, control group) at 9 and 15 months of age. Antibody titres against measles, mumps and rubella were measured using ELISA and against varicella using an immunofluorescence assay. Main outcome measures To demonstrate non-inferiority of the 2 vaccination regimens versus the control in terms of seroconversion rates, defined as a group difference with a lower bound of the 95% CI >−10% for each antigen, 43 days postdose 2. Parents/guardians recorded solicited local and general symptoms for a 4-day and 43-day period after each vaccine dose, respectively. Results Seroconversion rates postdose 1 ranged from 87.5% to 93.2% for measles, 83.3% to 86.1% for mumps and 98.7% to 100% for rubella across the 3 vaccine groups. The seroconversion rates postdose 2 were 100% for measles, mumps and rubella and at least 95.8% for varicella across the 3 vaccine groups. Non-inferiority of MMRV/MMRV and MMR/MMRV to MMR/MMR+V was achieved for all antigens, 43 days postdose 2. The 3 vaccination regimens were generally well tolerated in terms of solicited local and general symptoms. Conclusions The immune responses elicited by the MMRV/MMRV and MMR/MMRV vaccination regimens were non-inferior to those elicited by the MMR/MMR+V regimen for all antigens. The 3 vaccination schedules also exhibited an acceptable safety profile in Indian children. Trial registration number NCT00969436.
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 06 (01) , 001-006
Predictive value of blood culture in acute bacterial meningitis
To evaluate predictive value of blood culture as an effective alternative laboratory tool for isolation of causative organism in acute pyogenic meningitis. It is a hospital based prospective longitudinal hospital based study performed from May 2007 to May 2009. A total number of 310 children of age group 2 months-14 years who presented to the hospital with probability of bacterial meningitis were screened in the study. Eighty cases excluded by preset exclusion criteria and rest 230 formed the analytic sample. Pretreatment blood culture with concomitant lumbar puncture or lumbar puncture within 2 h of antibiotic administration for cerebrospinal fluid analysis was obtained. The main outcome parameter was the predictive value of blood culture for isolation of causative organism in acute bacterial meningitis. Blood culture revealed a sensitivity of 73.28% (95% confidence interval [CI]: 64.85%–80.63%), specificity of 87.88% (95% CI: 79.78%–93.58%), positive predictive value of 88.9% (95% CI: 81.40%–94.13%), negative predictive value of 71.31% (62.42%–79.14%), positive likelihood ratio of 5.97 and negative likelihood ratio of 0.30. Probability of isolation of causative organism by blood culture in bacterial meningitis was found to be highest among infants (82%) and least in children aged above 5 years (54.17%). When compared to gold standard cerebrospinal fluid diagnostic criteria, blood culture has a high sensitivity, specificity, positive predictive value and likelihood ratio to be an effective alternative laboratory tool for isolation of causative organism in acute bacterial meningitis especially in infants and younger children.
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 06 (01) , 001-006
Predictive value of blood culture in acute bacterial meningitis
To evaluate predictive value of blood culture as an effective alternative laboratory tool for isolation of causative organism in acute pyogenic meningitis. It is a hospital based prospective longitudinal hospital based study performed from May 2007 to May 2009. A total number of 310 children of age group 2 months-14 years who presented to the hospital with probability of bacterial meningitis were screened in the study. Eighty cases excluded by preset exclusion criteria and rest 230 formed the analytic sample. Pretreatment blood culture with concomitant lumbar puncture or lumbar puncture within 2 h of antibiotic administration for cerebrospinal fluid analysis was obtained. The main outcome parameter was the predictive value of blood culture for isolation of causative organism in acute bacterial meningitis. Blood culture revealed a sensitivity of 73.28% (95% confidence interval [CI]: 64.85%–80.63%), specificity of 87.88% (95% CI: 79.78%–93.58%), positive predictive value of 88.9% (95% CI: 81.40%–94.13%), negative predictive value of 71.31% (62.42%–79.14%), positive likelihood ratio of 5.97 and negative likelihood ratio of 0.30. Probability of isolation of causative organism by blood culture in bacterial meningitis was found to be highest among infants (82%) and least in children aged above 5 years (54.17%). When compared to gold standard cerebrospinal fluid diagnostic criteria, blood culture has a high sensitivity, specificity, positive predictive value and likelihood ratio to be an effective alternative laboratory tool for isolation of causative organism in acute bacterial meningitis especially in infants and younger children.
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 07 (01) , 001-007
Changing clinical profile of Dengue infection: A newer perspective in the pediatric population
Background: Traditionally complications of Dengue infection is limited to vascular and haematological system. The present study describes the changing clinico-epidemiological and laboratory profile of children hospitalized with dengue infection. Methods: Prospective observational study of children hospitalized with a diagnosis of dengue illness from October to December, 2010 at a tertiary care centre in Kolkata. Results: Of 50 children admitted with dengue infection, 24 had dengue fever (DF), 18 dengue hemorrhagic fever (DHF) and 8 had dengue shock syndrome (DSS). The mean age of affected children was 6.25 ± 3.34 years, mostly being males from rural areas. The common clinical manifestations were fever, rash, body ache, hemorrhagic manifestations and oedema. While headache and body ache was commoner among DF cases, rash and hemorrhagic manifestations were significantly more among DHF group. Incidence of altered sensorium, neck rigidity, fulminant hepatitis, and splenomegaly were significantly higher among the DHF/DSS group. 12% case fatality rate was found. Conclusion: Clinical manifestations of dengue seem to be changing. Fever, rash and bodyache are not the only clinical presentations. Encephalopathy, encephalitis, 6th cranial nerve palsy, fulminant hepatic failure, acute acalculous cholecystitis, myocarditis, myelitis, splenomegaly are some unusual but novel presentations of dengue in pediatric population that clinician in endemic area should be aware of though they are not mentioned in conventional guidelines Dengue is no longer restricted to urban areas but has propensity to spread to rural areas also.
- 28 July 2015
- Published by IOS Press in Journal of Pediatric Infectious Diseases
- Vol. 07 (01) , 001-007
Changing clinical profile of Dengue infection: A newer perspective in the pediatric population
Background: Traditionally complications of Dengue infection is limited to vascular and haematological system. The present study describes the changing clinico-epidemiological and laboratory profile of children hospitalized with dengue infection. Methods: Prospective observational study of children hospitalized with a diagnosis of dengue illness from October to December, 2010 at a tertiary care centre in Kolkata. Results: Of 50 children admitted with dengue infection, 24 had dengue fever (DF), 18 dengue hemorrhagic fever (DHF) and 8 had dengue shock syndrome (DSS). The mean age of affected children was 6.25 ± 3.34 years, mostly being males from rural areas. The common clinical manifestations were fever, rash, body ache, hemorrhagic manifestations and oedema. While headache and body ache was commoner among DF cases, rash and hemorrhagic manifestations were significantly more among DHF group. Incidence of altered sensorium, neck rigidity, fulminant hepatitis, and splenomegaly were significantly higher among the DHF/DSS group. 12% case fatality rate was found. Conclusion: Clinical manifestations of dengue seem to be changing. Fever, rash and bodyache are not the only clinical presentations. Encephalopathy, encephalitis, 6th cranial nerve palsy, fulminant hepatic failure, acute acalculous cholecystitis, myocarditis, myelitis, splenomegaly are some unusual but novel presentations of dengue in pediatric population that clinician in endemic area should be aware of though they are not mentioned in conventional guidelines Dengue is no longer restricted to urban areas but has propensity to spread to rural areas also.
- 1 September 2014
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 21 (9) , 1292-1300
Randomized, Open-Label Study of the Impact of Age on Booster Responses to the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Children in India
In this phase III, open-label, multicenter, and descriptive study in India, children primed with 3 doses (at ages 6, 10, and 14 weeks) of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were randomized (1:1) to receive a booster dose at 9 to 12 (early booster) or 15 to 18 months old (late booster) in order to evaluate impact of age at booster. We also evaluated a 2-dose catch-up vaccination plus an experimental booster dose in unprimed children age 12 to 18 months. The early booster, late booster, and catch-up vaccinations were administered to 74, 95, and 87 children, respectively; 66, 71, and 81 children, respectively, were included in the immunogenicity according-to-protocol cohort. One month postbooster, for each PHiD-CV serotype, ≥95.2% (early booster) and ≥93.8% (late booster) of the children had antibody concentrations of ≥0.2 μg/ml; ≥96.7% and ≥93.0%, respectively, had opsonophagocytic activity (OPA) titers of ≥8. The postbooster antibody geometric mean concentrations (GMCs) were in similar ranges for early and late boosters; the OPA titers appeared to be lower for most PHiD-CV serotypes (except 6B and 19F) after the early booster. After dose 2 and postbooster, for each PHiD-CV serotype, ≥88.6% and ≥96.3%, respectively, of the catch-up immunogenicity according-to-protocol cohort had antibody concentrations of ≥0.2 μg/ml; ≥71.4% and ≥90.6%, respectively, had OPA titers of ≥8. At least 1 serious adverse event was reported by 2 children in the early booster (skin infection and gastroenteritis) and 1 child in the catch-up group (febrile convulsion and urinary tract infection); all were resolved, and none were considered by the investigators to be vaccine related. PHiD-CV induced robust immune responses regardless of age at booster. Booster vaccination following 2 catch-up doses induced robust immune responses indicative of effective priming and immunological memory. (These studies have been registered at www.clinicaltrials.gov under registration no. NCT01030822 and NCT00814710; a protocol summary is available at www.gsk-clinicalstudyregister.com [study ID 112909]).
- 1 September 2014
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 21 (9) , 1292-1300
Randomized, Open-Label Study of the Impact of Age on Booster Responses to the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Children in India
In this phase III, open-label, multicenter, and descriptive study in India, children primed with 3 doses (at ages 6, 10, and 14 weeks) of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were randomized (1:1) to receive a booster dose at 9 to 12 (early booster) or 15 to 18 months old (late booster) in order to evaluate impact of age at booster. We also evaluated a 2-dose catch-up vaccination plus an experimental booster dose in unprimed children age 12 to 18 months. The early booster, late booster, and catch-up vaccinations were administered to 74, 95, and 87 children, respectively; 66, 71, and 81 children, respectively, were included in the immunogenicity according-to-protocol cohort. One month postbooster, for each PHiD-CV serotype, ≥95.2% (early booster) and ≥93.8% (late booster) of the children had antibody concentrations of ≥0.2 μg/ml; ≥96.7% and ≥93.0%, respectively, had opsonophagocytic activity (OPA) titers of ≥8. The postbooster antibody geometric mean concentrations (GMCs) were in similar ranges for early and late boosters; the OPA titers appeared to be lower for most PHiD-CV serotypes (except 6B and 19F) after the early booster. After dose 2 and postbooster, for each PHiD-CV serotype, ≥88.6% and ≥96.3%, respectively, of the catch-up immunogenicity according-to-protocol cohort had antibody concentrations of ≥0.2 μg/ml; ≥71.4% and ≥90.6%, respectively, had OPA titers of ≥8. At least 1 serious adverse event was reported by 2 children in the early booster (skin infection and gastroenteritis) and 1 child in the catch-up group (febrile convulsion and urinary tract infection); all were resolved, and none were considered by the investigators to be vaccine related. PHiD-CV induced robust immune responses regardless of age at booster. Booster vaccination following 2 catch-up doses induced robust immune responses indicative of effective priming and immunological memory. (These studies have been registered at www.clinicaltrials.gov under registration no. NCT01030822 and NCT00814710; a protocol summary is available at www.gsk-clinicalstudyregister.com [study ID 112909]).
- Open Access
- 1 January 2014
- Published by Medknow in Indian Journal of Public Health
- Vol. 58 (1) , 50-3
A study on smoking and associated psychosocial factors among adolescent students in Kolkata, India
Tobacco use among school children and adolescents is an increasing problem world-wide, particularly in the developing countries. A cross-sectional observational study was carried out in six co-educational high schools in Kolkata, West Bengal among 526 students of 15-19 years to determine the prevalence of smoking and to find out any difference among the smokers and non-smokers regarding factors related to family relations, peer group and personal characteristics. The overall rate of smoking was found to be 29.6%, mean age of initiation of smoking was earlier in males. Among smokers 75% students started smoking by 15 years. Smoking of father and peer group, family conflict and pornography addiction were found to have significant association with smoking of students. Early school health based interventions addressing these factors might help in effectively tackling this problem.
- 1 January 2014
- Published by Medknow in Indian Journal of Public Health
- Vol. 58 (1) , 50-3
Open AccessA study on smoking and associated psychosocial factors among adolescent students in Kolkata, India
Tobacco use among school children and adolescents is an increasing problem world-wide, particularly in the developing countries. A cross-sectional observational study was carried out in six co-educational high schools in Kolkata, West Bengal among 526 students of 15-19 years to determine the prevalence of smoking and to find out any difference among the smokers and non-smokers regarding factors related to family relations, peer group and personal characteristics. The overall rate of smoking was found to be 29.6%, mean age of initiation of smoking was earlier in males. Among smokers 75% students started smoking by 15 years. Smoking of father and peer group, family conflict and pornography addiction were found to have significant association with smoking of students. Early school health based interventions addressing these factors might help in effectively tackling this problem.
- Open Access
- 1 October 2013
- Vol. 23 (5) , 508-512
Measuring New Born Foot Length to Identify Small Babies in Need of Extra Care: a Cross-Sectional Hospital Based Study
The neonatal mortality rate (NMR) continues to remain quite high, one important cause being preterm deliveries. The main obstacle in the pathway towards decreasing NMR is identification of babies in need of extra care. To analyze the utility of newborn foot length as a proxy measure for birth weight and gestational age. A cross-sectional study done in a hospital of eastern India with 351 babies during 4 months. Right foot length of each recorded using a plastic, stiff ruler. 48.1% babies were preterm, 51.8% low birth weight (LBW) and 33.3% very low birth weight (VLBW). Foot length less than 7.75 cm has 92.3% sensitivity and 86.3% specificity for identification of preterm neonates. For identification of LBW babies (<2500 gm) a foot length less than 7.85cm has 100% sensitivity and 95.3% specificity. Foot length less than 6.85 cm has 100% sensitivity and 94.9% specifity for identification of VLBW babies (<1500 gm). Foot length may be used in the identification of LBW and preterm babies who are in need of extra care.
- 1 October 2013
- Vol. 23 (5) , 508-512
Open AccessMeasuring New Born Foot Length to Identify Small Babies in Need of Extra Care: a Cross-Sectional Hospital Based Study
The neonatal mortality rate (NMR) continues to remain quite high, one important cause being preterm deliveries. The main obstacle in the pathway towards decreasing NMR is identification of babies in need of extra care. To analyze the utility of newborn foot length as a proxy measure for birth weight and gestational age. A cross-sectional study done in a hospital of eastern India with 351 babies during 4 months. Right foot length of each recorded using a plastic, stiff ruler. 48.1% babies were preterm, 51.8% low birth weight (LBW) and 33.3% very low birth weight (VLBW). Foot length less than 7.75 cm has 92.3% sensitivity and 86.3% specificity for identification of preterm neonates. For identification of LBW babies (<2500 gm) a foot length less than 7.85cm has 100% sensitivity and 95.3% specificity. Foot length less than 6.85 cm has 100% sensitivity and 94.9% specifity for identification of VLBW babies (<1500 gm). Foot length may be used in the identification of LBW and preterm babies who are in need of extra care.
- Open Access
- 19 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (9) , 1903-1909
A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP–HepB–Hib vaccine in indian infants
Compliance with recommended vaccinations for Indian infants is facilitated by using combination vaccines to minimize the number of required injections. The ready-to-use, preservative free, fully-liquid combination DTwP–HepB–Hib vaccine, Quinvaxem®, offers convenience of administering five important vaccine antigens to infants in a single injection. This phase III, single-arm, multicenter study was designed to assess immunogenicity and safety of three doses of Quinvaxem® to Indian infants administered at 6, 10, and 14 weeks of age. Blood samples were taken prior to the first dose and at one month post last vaccination. Infants were observed clinically for any reaction approximately 30 min following each vaccination, and parents completed subject diaries for solicited local, systemic and any adverse events (AEs) following over a 5 d period. DTwP–HepB–Hib vaccine elicited strong immune responses that exceeded seroprotection/seroconversion thresholds against all vaccine antigens. At one month after third vaccination, percentages of infants achieving predefined protective antibody levels were 99% diphtheria; 100% tetanus; 98% Hepatitis B; 100% Hib short-term (≥ 0.15 µg/mL); 95% Hib long-term (≥ 1.0 µg/mL) protection; and relevant immune response was 99% for pertussis. The vaccine was well tolerated, with no vaccine-related serious AEs. Only one case of high fever (≥ 40°C) was reported. The most frequently reported reactions were mild to moderate tenderness and erythema. Frequencies of all AEs declined with subsequent vaccinations. This study demonstrated that this convenient, fully-liquid DTwP–HepB–Hib vaccine is highly immunogenic and has a acceptable safety profile for use in Indian infants. ClinicalTrials.gov Identifier: NCT01470287. Clinical Trials Registry of India Number: CTRI/2011/11/002118
- 19 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (9) , 1903-1909
Open AccessA phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP–HepB–Hib vaccine in indian infants
Compliance with recommended vaccinations for Indian infants is facilitated by using combination vaccines to minimize the number of required injections. The ready-to-use, preservative free, fully-liquid combination DTwP–HepB–Hib vaccine, Quinvaxem®, offers convenience of administering five important vaccine antigens to infants in a single injection. This phase III, single-arm, multicenter study was designed to assess immunogenicity and safety of three doses of Quinvaxem® to Indian infants administered at 6, 10, and 14 weeks of age. Blood samples were taken prior to the first dose and at one month post last vaccination. Infants were observed clinically for any reaction approximately 30 min following each vaccination, and parents completed subject diaries for solicited local, systemic and any adverse events (AEs) following over a 5 d period. DTwP–HepB–Hib vaccine elicited strong immune responses that exceeded seroprotection/seroconversion thresholds against all vaccine antigens. At one month after third vaccination, percentages of infants achieving predefined protective antibody levels were 99% diphtheria; 100% tetanus; 98% Hepatitis B; 100% Hib short-term (≥ 0.15 µg/mL); 95% Hib long-term (≥ 1.0 µg/mL) protection; and relevant immune response was 99% for pertussis. The vaccine was well tolerated, with no vaccine-related serious AEs. Only one case of high fever (≥ 40°C) was reported. The most frequently reported reactions were mild to moderate tenderness and erythema. Frequencies of all AEs declined with subsequent vaccinations. This study demonstrated that this convenient, fully-liquid DTwP–HepB–Hib vaccine is highly immunogenic and has a acceptable safety profile for use in Indian infants. ClinicalTrials.gov Identifier: NCT01470287. Clinical Trials Registry of India Number: CTRI/2011/11/002118
- 1 May 2013
- Published by Elsevier in Journal of Adolescent Health
- Vol. 52 (5) , 546-551
Patient Health Questionnaire-9 as an Effective Tool for Screening of Depression Among Indian Adolescents
- 1 May 2013
- Published by Elsevier in Journal of Adolescent Health
- Vol. 52 (5) , 546-551
Patient Health Questionnaire-9 as an Effective Tool for Screening of Depression Among Indian Adolescents